| Company Name | Novartis (Taiwan) Co., Ltd |
|---|---|
| Protocol Number | CAIN457A3404 |
| Title of Study | A non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment pattern of Secukinumab and current standard of care in patient with chronic plaque psoriasis eligible for systemic treatment in the Asia-Pacific and Middle East regions (REALIA) |
| Primary Objective | The proposed study aims to follow, over a period of 12 months, a large sample of chronic plaque psoriasis patients eligible for systemic therapy, living in countries in the Asia-Pacific and Middle East regions. This study will generate real-world evidence in patients from a large geographical region, where little has been published on the real-life treatment patterns and effectiveness of the different approaches used in chronic plaque psoriasis patients eligible for systemic treatment. This study will describe the patient characteristics, use of the different treatments in the routine clinical practice, and evaluate the effect on patient’s quality of life and the treatment outcome. |
| Number of Sites | 6 |
| Period of Study | From：Feb. 20, 2017 to：Aug. 31, 2019 |
| Number of Patients | 81人 |
| IRB Approval Date | Dec. 14, 2016 |
| Publication Plan / Date | Sep. 01, 2020 |
